Research
Hormonal
Modern GLP-1 receptor agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) offer significant, sustained weight loss with improved safety profiles compared to historical agents.
Modern obesity treatments like GLP-1 agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) are effective and safer than older drugs. They require medical supervision and are prescribed for specific patient profiles.
StrongSupportsHIGH confidence
The results of clinical trials of advanced therapeutic molecules, including gastrointestinal hormone receptor agonists, reinforce the belief that a breakthrough in the drug treatment of obesity is possible.
Why this rating
Based on multiple Phase III clinical trials and regulatory approvals.
Source
The history of the pharmacotherapy of obesity
M A Berkovskaya et al. · Problems of Endocrinology · 2025
DOI 10.14341/probl13469
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →